This product includes the webinar and SAM credit


Speaker

Eric H. Bernicker, MD

Moderator

Christopher R. Gilbert, DO

Description:

Targeted therapies for advanced lung cancers continue to expand rapidly. Viewers of this presentation will get an overview of the latest developments in the management of oncogene-addicted lung cancers and the need for close collaboration between medical oncologists and pathologists to make sure that patients receive optimal therapy.

Duration: 1 hr

Level of Instruction: Basic

Last day to purchase course and claim credit: December 31, 2020

Maximum SAM credit available: 1.0

Supported by an educational grant from AstraZeneca   


How to claim credit: To earn SAM credit, all learners must watch the webinar, achieve a minimum score of 80% on the online quiz, and complete an online survey. To access the quiz, click "Submit credit" on the course homepage or click on "My Credit" on the menu to the left and then "submit credit" for the appropriate course.

This course is approved by the American Board of Pathology for 1.0 SAM credits.Physicians should only claim credit commensurate with the extent of their participation in the activity. Participants must successfully complete the online modular exams (answering at least 80% of the questions in a topic module correctly).

SAM questions edited by: Rajyasree Emmadi, MD and Alan Brown, MD

* You may not submit SAMs and CME/CMLE credit for the same content.


You may also be interested in:

Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

 
Course Information
Course Date:
June 20, 2018
Course Objectives
  • Discuss the need for repeat biopsies upon progression so that therapies that target mechanisms of acquired resistance can be appropriately utilized.
  • Explain how targeted therapies are selected for patients with advanced adenocarcinoma of the lung.
Pre-Test for Best Practices in NSCLC Small Specimen Collection for Clinicians (+SAM)
Best Practices in NSCLC Small Specimen Collection for Clinicians
Post-Test for Best Practices in NSCLC Small Specimen Collection for Clinicians (+SAM)
QA Session
How to Claim SAM
Individual topic purchase: Selected
American Board of Pathology
Self-Assessment Module: 1.00
Products
NSCLC2 +SAM
AMP Regular Member: $0.00
AMP Technologist Member: $0.00
AMP Associate Member: $0.00
Non-member Price: $0.00